Pfizer calls for a second booster dose against covid-19 in the United States

Compartir
Compartir articulo

Pfizer and BioNTech announced on Tuesday that they have requested the United States Drug Administration (FDA) to approve an additional booster dose of the COVID-19 vaccine for people over 65 years of age.

For their demand, they were based on Israeli data and analyzed when the omicron variant was widely circulated, the company said in a statement.

According to Pfizer and BioNTech, the data show that “an additional booster dose of the messenger RNA vaccine increases immunogenicity” (the ability to induce an immune response) and “reduces the rate of identified infections and serious diseases”.

Therefore, the company asked the FDA for approval for emergency use.

bur differ/earl/dga